Brian Park, PharmD

Drug Information Specialist https://www.clinicalpainadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Opioid Addiction

Zimhi Approved for Emergency Treatment of Opioid Overdose

Brian Park, PharmD

October 21, 2021

Zimhi is intended for immediate administration as emergency therapy in settings where opioids may be present.

Migraine & Headache

Atogepant Approved for Preventive Treatment of Episodic Migraine

Brian Park, PharmD

October 5, 2021

The FDA has approved atogepant for the preventive treatment of episodic migraine in adults.

General Medicine

First Generic Version of Varenicline Now Available

Brian Park, PharmD

September 30, 2021

The first generic version of Chantix (varenicline) has been made available by Par Pharmaceutical, Inc.

General Medicine

Remdesivir Cuts Risk of Hospitalization in COVID-19 Patients at Risk for Disease Progression

Brian Park, PharmD

September 24, 2021

The trial included 584 nonhospitalized patients diagnosed with COVID-19 who were considered at high risk for disease progression based on comorbidities and age.

Woman with headache, computer illustration.

Migraine & Headache

Meloxicam/Rizatriptan Combination Under Review for Acute Migraine

Brian Park, PharmD

September 17, 2021

The FDA has accepted the NDA for AXS-07 for the acute treatment of migraine.

Opioid Addiction

FDA: Mandatory Opioid Prescriber Education to Be Discussed at Upcoming Workshop

Brian Park, PharmD

September 16, 2021

Overall opioid overdoses and opioid-involved deaths continue to increase.

Young woman suffering from abdominal pain or cramps while sitting on bed at home

Chronic Pain

FDA to Review Relugolix Combination Therapy for Endometriosis Pain

Brian Park, PharmD

September 14, 2021

The application is supported by data from the phase 3 SPIRIT program, which includes the SPIRIT 1 and SPIRIT 2 studies, as well as an open-label extension study.

A woman applying a topical analgesic for chronic pain

General Pain

Lidocaine HCI Topical Solution Recalled Due to Super Potency

Brian Park, PharmD

September 10, 2021

The recalled lot of Lidocaine HCl Topical Solution 4% (40mg/mL) was distributed at the wholesale and retail distribution levels.

Migraine & Headache

Nasal Spray Approved for Acute Treatment of Migraine

Brian Park, PharmD

September 10, 2021

The approval is supported by data from the phase 3 STOP 301 study, which evaluated the safety and tolerability of Trudhesa in 354 adults with migraine.